AZ-AXWAY
21.5.2013 08:01:06 CEST | Business Wire | Pressemeddelelse
Axway Managed File Transfer Solution Allows Capacity to Evolve and Advance without Migration to New Solution
With operations in more than 100 countries and more than 110,000 staff, global healthcare company Sanofi (NYSE: SNY EURONEXT: SAN) needed a way to streamline processes and transform its technology infrastructure into an efficient global network. To do this, Sanofi turned to Axway (NYSE Euronext: AXW.PA) to help make that transformation possible, enabling their infrastructure and operations (I&O) to go from a siloed structure of 26 legacy data centers to just three data centers.
In addition to consolidating data centers, Sanofi extended their existing deployment of Axway Managed File Transfer (MFT) , a comprehensive solution for both internal and external file transfers. With Axway MFT, Sanofi was able to ensure that all divisions, subsidiaries and new acquisitions were able to efficiently and securely exchange and manage data in a way that is uniform globally, while processing as many as 8,000 transfers each day. Not only did this increase efficiency across the organization, but it also reduced operational costs.
“Going from 26 data centers to three means that management costs will be reduced as well as expenditures related to personnel, telecommunications, storage, electricity and real estate,” said Mario Del Pin, EAI ETL Expert within Regional Service Delivery EMEA and Application Hosting Services, Global Infrastructure Services at Sanofi. “We have seen clear financial savings each year since the initiation of the I&O transformation. By 2014, we expect to achieve full payback with our financial savings equaling the financial investment.”
By relying on Axway technology for the evolution of its I&O, Sanofi is able to grow as a company without having to migrate to a completely new platform. All Axway Transfer CFT servers will be managed by a single entity per region, and Sanofi will use Axway Transfer CFT on all platforms and operating systems with exactly the same processes. This translates to administration savings because they are able to implement identical installation and processing procedures that any subsidiary can roll out on its own.
In addition, Axway is able to provide a streamlined and efficient way to govern the flow of data not only through existing legacy infrastructure, but also for information exchanged through the cloud and mobile. As the adoption of these tools continues to extend the network edge, companies are faced with the challenge of enabling workplace efficiency while still maintaining control, security and visibility. The new Axway 5 Suite provides companies, like Sanofi, with one unified approach for governing the flow of data as they transform and future-proof their infrastructure.
“Transformation is not a one-size-fits-all approach, and required changes depend on external and internal factors,” wrote analyst John Rakowski in a September 2012 Forrester Research, Inc. report titled, ‘Case Study: Sanofi’s Successful I&O Transformation Approach.’ “External market forces such as competition level and regulation are influential in direction, but speed and rate of change depend on internal people, process, and technology maturity.”
Using the Axway MFT solution, Sanofi had the tools necessary to ensure that its infrastructure could keep up with rapid company growth. As the company expanded, Sanofi was able to add enhanced features as needed using Axway’s solution.
“For large global companies with numerous divisions, subsidiaries and external changing partners it can be challenging to streamline infrastructure and technology into a seamless system with uniformity across the board,” said Bruno Cambounet, vice president, healthcare EMEA, Axway. “Not only was Sanofi able to effectively evolve their company to meet these demands, but they were able to do it using an existing product instead of transitioning to a new one.”
Sanofi has been using Axway MFT solutions for years, and their recent data center consolidation project demonstrates the solutions’ capacity to evolve and advance as a company prepares for the future without having to migrate to a new solution. This is a testament to Axway’s commitment to helping large companies find solutions that allow them to better manage and secure data through the evolution of managed file transfer.
To learn more about how Sanofi and Axway work together, download the case study here: http://www2.axway.com/en/lp/pharma-solutions-info-bundle
Follow Axway on Twitter: https://twitter.com/Axway
Read more on the Axway blog: http://blogs.axway.com/category/managed-file-transfer/page/3/
About Axway
Axway (NYSE Euronext: AXW.PA), a market leader in governing the flow of data, is a global software company with more than 11,000 public- and private-sector customers in 100 countries. For more than a decade, Axway has empowered leading organizations around the world with proven solutions that help manage business-critical interactions through the exchange of data flowing across the enterprise, among B2B communities, cloud and mobile devices. Our award-winning solutions span business-to-business integration, managed file transfer, API and identity management, and email security– offered on premise and in the Cloud with professional and managed services.
Axway is registered in France with headquarters in the United States and 22 offices in 17 countries. More information is available at www.axway.com .
About Axway 5 Suite
Axway 5 Suite offers control and optimization of the flow of data through integration, visibility, policy, security and reliability to govern business-to-business interactions, communities, systems and data types — within and beyond the enterprise edge.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contact:
Media
SHIFT Communications
Jennifer Usher,
415-591-8456
axway@shiftcomm.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum